250 related articles for article (PubMed ID: 28265581)
1. Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant Recipients.
Toyoda M; Shin BH; Ge S; Mirocha J; Thomas D; Chu M; Rodriguez E; Chao C; Petrosyan A; Galera OA; Vo A; Choi J; Peng A; Kahwaji J; Jordan SC
J Immunol Res; 2017; 2017():5672523. PubMed ID: 28265581
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus Immunity After Alemtuzumab Induction in Desensitized Kidney Transplant Patients.
Ge S; Karasyov A; Sinha A; Petrosyan A; Lovato D; Thomas DL; Vo A; Jordan SC; Toyoda M
Transplantation; 2017 Jul; 101(7):1720-1726. PubMed ID: 27841845
[TBL] [Abstract][Full Text] [Related]
3. Polyomavirus BK viremia in kidney transplant recipients after desensitization with IVIG and rituximab.
Barbosa D; Kahwaji J; Puliyanda D; Mirocha J; Reinsmoen N; Lai CH; Villicana R; Peng A; Jordan SC; Vo A; Toyoda M
Transplantation; 2014 Apr; 97(7):755-61. PubMed ID: 24686425
[TBL] [Abstract][Full Text] [Related]
4. Immunologic parameters and viral infections in patients desensitized with intravenous immunoglobulin and rituximab.
Ge S; Pao A; Vo A; Deer N; Karasyov A; Petrosyan A; Kahwaji J; Lukovsky M; Chai NN; Aguiluz A; Mirocha J; Jordan SC; Toyoda M
Transpl Immunol; 2011 Apr; 24(3):142-8. PubMed ID: 21122815
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Alemtuzumab Induction in Highly Sensitized Pediatric Renal Transplant Recipients.
Kim IK; Choi J; Vo AA; Kang A; Patel M; Toyoda M; Mirocha J; Kamil ES; Cohen JL; Louie S; Galera O; Jordan SC; Puliyanda DP
Transplantation; 2017 Apr; 101(4):883-889. PubMed ID: 27495773
[TBL] [Abstract][Full Text] [Related]
6. Viral-specific cytotoxic T-cell responses in HLA-sensitized kidney transplant patients maintained on everolimus and low-dose tacrolimus.
Ge S; Chu M; Tang J; Kahwaji J; Karasyov A; Lovato D; Vo A; Choi J; Jordan SC; Zhang R; Toyoda M
Transpl Infect Dis; 2022 Apr; 24(2):e13805. PubMed ID: 35213773
[TBL] [Abstract][Full Text] [Related]
7. Analysis of subcutaneous (SQ) alemtuzumab induction therapy in highly sensitized patients desensitized with IVIG and rituximab.
Vo AA; Wechsler EA; Wang J; Peng A; Toyoda M; Lukovsky M; Reinsmoen N; Jordan SC
Am J Transplant; 2008 Jan; 8(1):144-9. PubMed ID: 17973966
[TBL] [Abstract][Full Text] [Related]
8. Pretransplant prophylactic rituximab to prevent Epstein-Barr virus (EBV) viremia in EBV-seronegative kidney transplant recipients from EBV-seropositive donors: results of a pilot study.
Schachtner T; Reinke P
Transpl Infect Dis; 2016 Dec; 18(6):881-888. PubMed ID: 27632022
[TBL] [Abstract][Full Text] [Related]
9. Antigenic competition in the generation of multi-virus-specific cell lines for immunotherapy of human cytomegalovirus, polyomavirus BK, Epstein-Barr virus and adenovirus infection in haematopoietic stem cell transplant recipients.
Roubalová K; Němečková Š; Kryštofová J; Hainz P; Pumannová M; Hamšíková E
Immunol Lett; 2020 Dec; 228():64-69. PubMed ID: 33031870
[TBL] [Abstract][Full Text] [Related]
10. EBV, CMV, and BK viral infections in pediatric kidney transplantation: Frequency, risk factors, treatment, and outcomes.
Levi S; Davidovits M; Alfandari H; Dagan A; Borovitz Y; Bilavsky E; Landau D; Haskin O
Pediatr Transplant; 2022 May; 26(3):e14199. PubMed ID: 34817112
[TBL] [Abstract][Full Text] [Related]
11. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients.
Hill P; Cross NB; Barnett AN; Palmer SC; Webster AC
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004759. PubMed ID: 28073178
[TBL] [Abstract][Full Text] [Related]
12. The impact of donor viral replication at transplant on recipient infections posttransplant: a prospective study.
Verghese PS; Schmeling DO; Knight JA; Matas AJ; Balfour HH
Transplantation; 2015 Mar; 99(3):602-8. PubMed ID: 25148381
[TBL] [Abstract][Full Text] [Related]
13. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation.
Vo AA; Peng A; Toyoda M; Kahwaji J; Cao K; Lai CH; Reinsmoen NL; Villicana R; Jordan SC
Transplantation; 2010 May; 89(9):1095-102. PubMed ID: 20110854
[TBL] [Abstract][Full Text] [Related]
14. JC polyomavirus viremia and progressive multifocal leukoencephalopathy in human leukocyte antigen-sensitized kidney transplant recipients desensitized with intravenous immunoglobulin and rituximab.
Toyoda M; Thomas D; Ahn G; Kahwaji J; Mirocha J; Chu M; Vo A; Suviolahti E; Ge S; Jordan SC
Transpl Infect Dis; 2015 Dec; 17(6):838-47. PubMed ID: 26437369
[TBL] [Abstract][Full Text] [Related]
15. Six-year outcomes in broadly HLA-sensitized living donor transplant recipients desensitized with intravenous immunoglobulin and rituximab.
Kahwaji J; Jordan SC; Najjar R; Wongsaroj P; Choi J; Peng A; Villicana R; Vo A
Transpl Int; 2016 Dec; 29(12):1276-1285. PubMed ID: 27529314
[TBL] [Abstract][Full Text] [Related]
16. Reactivation of latent viruses in individuals receiving rituximab for new onset type 1 diabetes.
Kroll JL; Beam C; Li S; Viscidi R; Dighero B; Cho A; Boulware D; Pescovitz M; Weinberg A;
J Clin Virol; 2013 Jun; 57(2):115-9. PubMed ID: 23422292
[TBL] [Abstract][Full Text] [Related]
17. BKV, CMV, and EBV Interactions and their Effect on Graft Function One Year Post-Renal Transplantation: Results from a Large Multi-Centre Study.
Blazquez-Navarro A; Dang-Heine C; Wittenbrink N; Bauer C; Wolk K; Sabat R; Westhoff TH; Sawitzki B; Reinke P; Thomusch O; Hugo C; Or-Guil M; Babel N
EBioMedicine; 2018 Aug; 34():113-121. PubMed ID: 30072213
[TBL] [Abstract][Full Text] [Related]
18. Pre-Hematopoietic Stem Cell Transplantation Rituximab for Epstein-Barr Virus and Post-Lymphoproliferative Disorder Prophylaxis in Alemtuzumab Recipients.
Patel C; Pasciolla M; Abramova R; Salerno D; Gomez-Arteaga A; Shore TB; Orfali N; Mayer S; Hsu J; Phillips AA; Chaekal OK; Satlin MJ; Soave R; Kodiyanplakkal RPL; Drelick A; Plate M; Besien KV
Transplant Cell Ther; 2023 Feb; 29(2):132.e1-132.e5. PubMed ID: 36334653
[TBL] [Abstract][Full Text] [Related]
19. Management of BK viremia is associated with a lower risk of subsequent cytomegalovirus infection in kidney transplant recipients.
Jorgenson MR; Descourouez JL; Lyu B; Astor BC; Saddler CM; Mandelbrot DA; Parajuli S
Clin Transplant; 2020 Mar; 34(3):e13798. PubMed ID: 31994787
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the impact of pre-transplant desensitization utilizing a plasmapheresis and low-dose intravenous immunoglobulin protocol on BK viremia in renal transplant recipients.
Gabardi S; Townsend K; Martin ST; Chandraker A
Transpl Infect Dis; 2013 Aug; 15(4):361-8. PubMed ID: 23647907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
